Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer

IMPORTANCE: The neoadjuvant treatment options for ERBB2-positive (also known as HER2-positive) breast cancer are associated with different rates of pathologic complete response (pCR). The KATHERINE trial showed that adjuvant trastuzumab emtansine (T-DM1) can reduce recurrence in patients with residu...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunst, Natalia, Wang, Shi-Yi, Hood, Annette, Mougalian, Sarah S., DiGiovanna, Michael P., Adelson, Kerin, Pusztai, Lajos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2020
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684449/
https://www.ncbi.nlm.nih.gov/pubmed/33226431
http://dx.doi.org/10.1001/jamanetworkopen.2020.27074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684449/
https://www.ncbi.nlm.nih.gov/pubmed/33226431
http://dx.doi.org/10.1001/jamanetworkopen.2020.27074

Ejemplares similares